Literature DB >> 6417156

Plasma growth hormone response to growth hormone-releasing factor in acromegalic patients.

T Shibasaki, K Shizume, A Masuda, M Nakahara, N Hizuka, M Miyakawa, K Takano, H Demura, I Wakabayashi, N Ling.   

Abstract

Synthetic growth hormone-releasing factor (hpGRF-44) (100 micrograms) was administered intravenously to ten acromegalic patients. The time when the peak of plasma GH occurred as well as the magnitude of the response were highly variable among these ten patients. From the GH response patterns the ten acromegalic patients were tentatively classified into three groups: (1) those highly GRF-dependent whose GH level increased to four times basal, (2) those moderately GRF-dependent whose GH level rose to less than two times basal and (3) those GRF-resistant whose GH level did not change. These data suggest that there may be differences in the GRF-receptor system in pituitary adenomas causing acromegaly.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6417156     DOI: 10.1210/jcem-58-1-215

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Endocrinological differentiation of primary hypothalamic and pituitary disease.

Authors:  E E Müller
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

2.  Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men.

Authors:  S M Rosenthal; J A Hulse; S L Kaplan; M M Grumbach
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

3.  The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy.

Authors:  M Giusti; A Lomeo; M Monachesi; G Mazzocchi; R Attanasio; P Sessarego; D Mignone; P Del Monte; G Giordano
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

4.  Effects of growth hormone-releasing hormone (GHRH) on densely granulated somatotroph adenomas and sparsely granulated somatotroph adenomas in vitro: a morphological and functional investigation.

Authors:  S Kawakita; S L Asa; K Kovacs
Journal:  J Endocrinol Invest       Date:  1989 Jul-Aug       Impact factor: 4.256

5.  Human pancreatic growth hormone-releasing factor (hpGRF-44) in acromegaly before and after adenomectomy. Modifications induced by somatostatin (GHRIH) infusion.

Authors:  M Arosio; B Ambrosi; L Guglielmino; G Faglia
Journal:  J Endocrinol Invest       Date:  1985-10       Impact factor: 4.256

6.  Study on the mechanism of abnormal growth hormone (GH) secretion in anorexia nervosa: no evidence of involvement of a low somatomedin-C level in the abnormal GH secretion.

Authors:  A Masuda; T Shibasaki; M Hotta; H Suematsu; K Shizume
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

7.  The effects of growth hormone-releasing factor (GRF) and dopamine on growth hormone (GH) secretion in acromegaly.

Authors:  M Giusti; A Lomeo; G Mazzocchi; D Mignone; P Sessarego; M Monachesi; G Giordano
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

8.  Growth hormone responses to hp GRF 1-44 amide, bromocriptine and stress in acromegaly are correlated.

Authors:  P E Belchetz
Journal:  Postgrad Med J       Date:  1987-04       Impact factor: 2.401

Review 9.  Growth Hormone-Releasing Hormone in Diabetes.

Authors:  Leonid E Fridlyand; Natalia A Tamarina; Andrew V Schally; Louis H Philipson
Journal:  Front Endocrinol (Lausanne)       Date:  2016-10-10       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.